Northwire Canada EditionThursday, October 15, 2026
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Other Routine +

Verano Announces $20 Million Share Repurchase Authorization

Buyback signals confidence post-rescheduling

Executive Summary
  • Verano Holdings Corp. authorized a Normal Course Issuer Bid (NCIB) to repurchase up to $20 million of common stock.
  • The program allows for the purchase of approximately 18,219,090 shares, representing roughly 5% of outstanding shares.
  • Program duration is set for 12 months ending April 30, 2027.
  • Execution will occur via ATB Capital Markets Corp on Cboe Canada, subject to Rule 10b-18 constraints (daily limit 25% of average daily volume).
  • Management cites the authorization as a tool for capital optionality following the Schedule III medical cannabis designation and strengthened balance sheet.
  • This follows the April 23, 2026 announcement confirming Cannabis rescheduling from Schedule I to Schedule III under the Controlled Substances Act.
Material Impact
  • The $20 million buyback is a positive signal of management confidence in cash flow generation but does not fundamentally alter the valuation thesis established by the recent regulatory changes.
  • Given the company's market capitalization of approximately $451 million, the buyback represents roughly 4.4% of equity value, which is meaningful but standard for a company with this level of liquidity ($83M cash + credit facilities).
  • The news validates the March 2026 refinancing success and the April 2026 Schedule III rescheduling catalyst by demonstrating available capital to deploy.
  • It is categorized as Routine - Positive because share repurchase authorizations are expected corporate actions once liquidity constraints are resolved, rather than a sudden market-moving event like an M&A deal or major investor entry.
VRNO · Price
Company Overview
  • Verano Holdings Corp. is a multi-state operator in medical cannabis with operations in 13 states.
  • Flagship Project/Operations: Zen Leaf dispensaries (retail) and MÜV dispensaries (Florida).
  • Footprint: 160 dispensaries nationwide, 15 production facilities, over 1.1 million sq ft of cultivation capacity.
  • Recent Expansion: Secured conditional vertical license in Texas (Phase 1), pending final approval; redomiciled from British Columbia to Nevada for tax and regulatory benefits.
  • Product Innovation: Launched Swift Lifts pre-roll brand and HYPHEN pod system; partnerships with Flower by Edie Parker in Florida.
Read the original news release →

More from VERANO HOLDINGS CORP.